Biotech’s new­born uni­corn Sana grabs Har­vard tech aimed at slip­ping en­gi­neered stem cells past the im­mune sys­tem

Af­ter lead­ing one of the ear­ly pi­o­neers in cus­tomized can­cer ther­a­pies us­ing pa­tient cells for CAR-T, the found­ing ex­ecs at Sana Biotech­nol­o­gy are now nail­ing down the IP for a new gen­er­a­tion of off-the-shelf cell ther­a­pies that they be­lieve can have built-in pro­tec­tion against an im­mune re­sponse. And they’re throw­ing in some open ac­cess tech on gene edit­ing to boot.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER